

Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations

NCT06673290

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	West China Hospital
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (5)

- Presenting a LM with the following characteristics:
- Male and female;
- Between 0 and 18 years of age;
- LM diagnosis was confirmed by local investigators and by consensus of our multidisciplinary vascular anomaly group at the West China Hospital of Sichuan University based on:
- Biopsy; Compatible MRI findings; History and clinical features.

Exclusion (18)

- Patients contraindicated for the administration of sirolimus (e.g., those with an allergy to sirolimus or other rapamycin analog)
- Exposure to chemotherapy, embolization, corticosteroids, propranolol, sclerotherapy or any other investigational agents within 1 weeks before enrolment on study;
- Patients had a history of a major surgery within 2 weeks before enrollment;
- Patients who have a history of treatment with sirolimus or other mTOR inhibitor;
- Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of enrollment;

... and 13 more (see full listing online)

Locations (1 total)

West China Hospital of Sichuan University, Chengdu, Sichuan, China